The stock of Concordia International Corp (NASDAQ:CXRX) reached all time low today, Oct, 17 and still has $3.20 target or 10.00% below today’s $3.55 share price. This indicates more downside for the $187.23M company. This technical setup was reported by Barchart.com. If the $3.20 PT is reached, the company will be worth $18.72M less.
Trading stocks at an all time low is not easy. Stock at an all time low usually experience even more downside due to very negative fundament. Even thought the pullback rate is high, shorting is not an easy job because the risk of being wrong is big and the risk-reward ratio is always worse than if trading lon only. About 1.07M shares traded hands. Concordia International Corp (NASDAQ:CXRX) has declined 89.17% since March 14, 2016 and is downtrending. It has underperformed by 94.79% the S&P500.
Analysts await Concordia International Corp (NASDAQ:CXRX) to report earnings on November, 10. They expect $1.35 EPS, up 3.05% or $0.04 from last year’s $1.31 per share. CXRX’s profit will be $71.20M for 0.66 P/E if the $1.35 EPS becomes a reality. After $1.21 actual EPS reported by Concordia International Corp for the previous quarter, Wall Street now forecasts 11.57% EPS growth.
Concordia International Corp (NASDAQ:CXRX) Ratings Coverage
Out of 9 analysts covering Concordia Healthcare Corp. (NASDAQ:CXRX), 5 rate it a “Buy”, 0 “Sell”, while 4 “Hold”. This means 56% are positive. Concordia Healthcare Corp. has been the topic of 18 analyst reports since August 11, 2015 according to StockzIntelligence Inc. GMP Securities downgraded the stock to “Hold” rating in Monday, August 15 report. IBC downgraded the shares of CXRX in a report on Monday, August 15 to “Underperformer” rating. The rating was maintained by Scotia Capital on Tuesday, September 29 with “Sector Outperform”. The rating was upgraded by Scotia Capital on Monday, September 19 to “Sector Perform”. On Thursday, October 1 the stock rating was reinitiated by RBC Capital Markets with “Outperform”. TD Securities downgraded the shares of CXRX in a report on Thursday, August 4 to “Hold” rating. On Friday, October 16 the stock rating was maintained by Scotia Capital with “Sector Outperform”. The stock of Concordia International Corp (NASDAQ:CXRX) has “Buy” rating given on Tuesday, March 29 by Laurentian. On Monday, November 30 the stock rating was initiated by IBC with “Sector Perform”. The stock of Concordia International Corp (NASDAQ:CXRX) earned “Buy” rating by Canaccord Genuity on Tuesday, August 11.
According to Zacks Investment Research, “Concordia International Corp is a diverse pharmaceutical company which focused on legacy pharmaceutical products and orphan drugs. The company also markets orphan drugs through its Orphan Drug Division, currently consisting of Photofrin(R) for the treatment of certain rare forms of cancer, which is currently undergoing testing for potential new indications. Concordia International Corp, formerly known as Concordia Healthcare Corp, is headquartered in Oakville, Canada.”
More important recent Concordia International Corp (NASDAQ:CXRX) news were published by: Business.Financialpost.com which released: “Concordia International Corp. faces much more downside â€“ CIBC” on October 14, 2016, also Business.Financialpost.com published article titled: “Concordia International Corp takeover unlikely â€“ Goldman”, Globenewswire.com published: “DEADLINE ALERT: Rigrodsky & Long, P.A. Reminds Shareholders Of Concordia …” on September 29, 2016. More interesting news about Concordia International Corp (NASDAQ:CXRX) was released by: Moodys.com and their article: “Moody’s assigns B1 to Concordia’s new secured notes; outlook to negative” with publication date: October 06, 2016.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.